Exosome-mediated metabolic reprogramming: the emerging role in tumor microenvironment remodeling and its influence on cancer progression

Enli Yang; Xuan Wang; Zhiyuan Gong; Miao Yu; Haiwei Wu; Dongsheng Zhang

doi:10.1038/s41392-020-00359-5

journal article Open Access Oct 19, 2020

Exosome-mediated metabolic reprogramming: the emerging role in tumor microenvironment remodeling and its influence on cancer progression

Enli Yang Xuan Wang

Signal Transduction and Targeted Therapy Vol. 5 No. 1 · Springer Science and Business Media LLC

View at Publisher Save 10.1038/s41392-020-00359-5

Abstract

AbstractMetabolic reprogramming is reported to be one of the hallmarks of cancer, which is an adaptive mechanism by which fast-growing cancer cells adapt to their increasing energy demands. Recently, extracellular vesicles (EVs) known as exosomes have been recognized as crucial signaling mediators in regulating the tumor microenvironment (TME). Meanwhile, the TME is a highly heterogeneous ecosystem incorporating cancer cells, fibroblasts, adipocytes, endothelial cells, mesenchymal stem cells, and extracellular matrix. Accumulated evidence indicates that exosomes may transfer biologically functional molecules to the recipient cells, which facilitate cancer progression, angiogenesis, metastasis, drug resistance, and immunosuppression by reprogramming the metabolism of cancer cells and their surrounding stromal cells. In this review, we present the role of exosomes in the TME and the underlying mechanism of how exosomes exacerbate tumor development through metabolic reprogramming. In addition, we will also discuss the potential role of exosomes targeting metabolic process as biomarkers for tumor diagnosis and prognosis, and exosomes-mediated metabolic reprogramming as potential targets for cancer therapy. Furthermore, a better understanding of the link between exosomes and metabolic reprogramming, and their impact on cancer progression, would provide novel insights for cancer prevention and treatment in the future.

Topics

No keywords indexed for this article. Browse by subject →

References

145

[1]

Hallmarks of Cancer: The Next Generation

Douglas Hanahan, Robert A. Weinberg

Cell 2011 10.1016/j.cell.2011.02.013

[2]

Pavlova, N. N. & Thompson, C. B. The emerging hallmarks of cancer metabolism. Cell Metab. 23, 27–47 (2016). 10.1016/j.cmet.2015.12.006

[3]

On the Origin of Cancer Cells

Otto Warburg

Science 1956 10.1126/science.123.3191.309

[4]

Exosome mediated communication within the tumor microenvironment

Lara Milane, Amit Singh, George Mattheolabakis et al.

Journal of Controlled Release 2015 10.1016/j.jconrel.2015.06.029

[5]

Tkach, M. & Thery, C. Communication by extracellular vesicles: where we are and where we need to go. Cell 164, 1226–1232 (2016). 10.1016/j.cell.2016.01.043

[6]

Gangoda, L., Boukouris, S., Liem, M., Kalra, H. & Mathivanan, S. Extracellular vesicles including exosomes are mediators of signal transduction: are they protective or pathogenic? Proteomics 15, 260–271 (2015). 10.1002/pmic.201400234

[7]

Li, K., Chen, Y., Li, A., Tan, C. & Liu, X. Exosomes play roles in sequential processes of tumor metastasis. Int. J. Cancer 144, 1486–1495 (2019). 10.1002/ijc.31774

[8]

Fontana, S., Saieva, L., Taverna, S. & Alessandro, R. Contribution of proteomics to understanding the role of tumor-derived exosomes in cancer progression: state of the art and new perspectives. Proteomics 13, 1581–1594 (2013). 10.1002/pmic.201200398

[9]

Extracellular vesicles swarm the cancer microenvironment: from tumor–stroma communication to drug intervention

F Wendler, R Favicchio, T Simon et al.

Oncogene 2017 10.1038/onc.2016.253

[10]

Biological properties of extracellular vesicles and their physiological functions

María Yáñez‐Mó, Pia R.‐M. Siljander, Zoraida Andreu et al.

Journal of Extracellular Vesicles 2015 10.3402/jev.v4.27066

[11]

Puhka, M. et al. Metabolomic profiling of extracellular vesicles and alternative normalization methods reveal enriched metabolites and strategies to study prostate cancer-related changes. Theranostics 7, 3824–3841 (2017). 10.7150/thno.19890

[12]

Li, I. & Nabet, B. Y. Exosomes in the tumor microenvironment as mediators of cancer therapy resistance. Mol. Cancer 18, 32 (2019). 10.1186/s12943-019-0975-5

[13]

Zhang, L. & Yu, D. Exosomes in cancer development, metastasis, and immunity. Biochim. Biophys. Acta Rev. Cancer 1871, 455–468 (2019). 10.1016/j.bbcan.2019.04.004

[14]

Milman, N., Ginini, L. & Gil, Z. Exosomes and their role in tumorigenesis and anticancer drug resistance. Drug Resist Updat. 45, 1–12 (2019). 10.1016/j.drup.2019.07.003

[15]

Exosomes: composition, biogenesis and function

Clotilde Théry, Laurence Zitvogel, Sebastian Amigorena

Nature Reviews Immunology 2002 10.1038/nri855

[16]

Biogenesis, Secretion, and Intercellular Interactions of Exosomes and Other Extracellular Vesicles

Marina Colombo, Graça Raposo, Clotilde Théry

Annual Review of Cell and Developmental Biology 2014 10.1146/annurev-cellbio-101512-122326

[17]

Kowal, J., Tkach, M. & Thery, C. Biogenesis and secretion of exosomes. Curr. Opin. Cell Biol. 29, 116–125 (2014). 10.1016/j.ceb.2014.05.004

[18]

Rab27a and Rab27b control different steps of the exosome secretion pathway

Matias Ostrowski, Nuno B. Carmo, Sophie Krumeich et al.

Nature Cell Biology 2010 10.1038/ncb2000

[19]

Song, L. et al. KIBRA controls exosome secretion via inhibiting the proteasomal degradation of Rab27a. Nat. Commun. 10, 1639 (2019). 10.1038/s41467-019-09720-x

[20]

Lauwers, E. et al. Hsp90 mediates membrane deformation and exosome release. Mol. Cell. 71, 689–702 (2018). 10.1016/j.molcel.2018.07.016

[21]

Zou, W., et al. Exosome release is regulated by mTORC1. Adv. Sci. https://doi.org/10.1002/advs.201801313 (2019). 10.1002/advs.201801313

[22]

Barros, F. M. et al. Exosomes and immune response in cancer: friends or foes. Front. Immunol. 9, 730 (2018). 10.3389/fimmu.2018.00730

[23]

Coumans, F. et al. Methodological guidelines to study extracellular vesicles. Circ. Res. 120, 1632–1648 (2017). 10.1161/circresaha.117.309417

[24]

Li, P., Kaslan, M., Lee, S. H., Yao, J. & Gao, Z. Progress in exosome isolation techniques. Theranostics 7, 789–804 (2017). 10.7150/thno.18133

[25]

Jeppesen, D. K. et al. Comparative analysis of discrete exosome fractions obtained by differential centrifugation. J. Extracell. Vesicles 3, 25011 (2014). 10.3402/jev.v3.25011

[26]

Lehuédé, C. et al. Metabolic plasticity as a determinant of tumor growth and metastasis. Cancer Res. 76, 5201–5208 (2016). 10.1158/0008-5472.can-16-0266

[27]

Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation

Matthew G. Vander Heiden, Lewis C. Cantley, Craig B. Thompson

Science 2009 10.1126/science.1160809

[28]

Liberti, M. V. & Locasale, J. W. Review e the Warburg effect: how does it benefit cancer cells? Trends Biochem. Sci. 41, 287 (2016). 10.1016/j.tibs.2016.01.004

[29]

Currie, E. et al. Cellular fatty acid metabolism and cancer. Cell Metab. 18, 153–161 (2013). 10.1016/j.cmet.2013.05.017

[30]

Migita, T. et al. ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer. Cancer Res. 68, 8547–8554 (2008). 10.1158/0008-5472.can-08-1235

[31]

Chajes, V. et al. Acetyl-CoA carboxylase alpha is essential to breast cancer cell survival. Cancer Res. 66, 5287–5294 (2006). 10.1158/0008-5472.can-05-1489

[32]

Carracedo, A., Cantley, L. C. & Pandolfi, P. P. Cancer metabolism: fatty acid oxidation in the limelight. Nat. Rev. Cancer 13, 227–232 (2013). 10.1038/nrc3483

[33]

Pike, L. S. et al. Inhibition of fatty acid oxidation by etomoxir impairs NADPH production and increases reactive oxygen species resulting in ATP depletion and cell death in human glioblastoma cells. Biochim. Biophys. Acta 1807, 726–734 (2011). 10.1016/j.bbabio.2010.10.022

[34]

Hensley, C. T. et al. Glutamine and cancer:cell biology, physiology, and clinical opportunities. J. Clin. Invest. 123, 3678–3684 (2013). 10.1172/jci69600

[35]

Gao, P. et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature 458, 762–765 (2009). 10.1038/nature07823

[36]

Dias, A. S. et al. Metabolic crosstalk in the breast cancer microenvironment. Eur. J. Cancer 121, 154–171 (2019). 10.1016/j.ejca.2019.09.002

[37]

Giraldo, N. A. et al. The clinical role of the TME in solid cancer. Br. J. Cancer 120, 45–53 (2019). 10.1038/s41416-018-0327-z

[38]

Tan, S. et al. Exosomal miRNAs in tumor microenvironment. J. Exp. Clin. Cancer Res. 39, 67 (2020). 10.1186/s13046-020-01570-6

[39]

Ostman, A. & Augsten, M. Cancer-associated fibroblasts and tumor growth–bystanders turning into key players. Curr. Opin. Genet. Dev. 19, 67–73 (2009). 10.1016/j.gde.2009.01.003

[40]

Sazeides, C. & Le, A. Metabolic relationship between cancer-associated fibroblasts and cancer cells. Adv. Exp. Med. Biol. 1063, 149–165 (2018). 10.1007/978-3-319-77736-8_11

[41]

Chen, X. & Song, E. Turning foes to friends: targeting cancer-associated fibroblasts. Nat. Rev. Drug Discov. 18, 99–115 (2019). 10.1038/s41573-018-0004-1

[42]

Xing, F., Saidou, J. & Watabe, K. Cancer associated fibroblasts (CAFs) in tumor microenvironment. Front Biosci. 15, 166–179 (2010). 10.2741/3613

[43]

Martinez-Outschoorn, U. E. et al. Stromal-epithelial metabolic coupling in cancer: integrating autophagy and metabolism in the tumor microenvironment. Int. J. Biochem. Cell Biol. 43, 1045–1051 (2011). 10.1016/j.biocel.2011.01.023

[44]

Diehl, K. et al. Nuclear factor E2-related factor-2 has a differential impact on MCT1 and MCT4 lactate carrier expression in colonic epithelial cells: a condition favoring metabolic symbiosis between colorectal cancer and stromal cells. Oncogene 37, 39–51 (2018). 10.1038/onc.2017.299

[45]

Raudenska, M., Gumulec, J., Balvan, J. & Masarik, M. Caveolin-1 in oncogenic metabolic symbiosis. Int. J. Cancer 10, 1002 (2020).

[46]

Caveolin-1 in the regulation of cell metabolism: a cancer perspective

Zeribe Chike Nwosu, Matthias Philip Ebert, Steven Dooley et al.

Molecular Cancer 2016 10.1186/s12943-016-0558-7

[47]

Bonuccelli, G. et al. The reverse Warburg effect: glycolysis inhibitors prevent the tumor promoting effects of caveolin-1 deficient cancer associated fibroblasts. Cell Cycle 9, 1960–1971 (2010). 10.4161/cc.9.10.11601

[48]

Martinez-Outschoorn, U. E., Sotgia, F. & Lisanti, M. P. Caveolae and signalling in cancer. Nat. Rev. Cancer 15, 225 (2015). 10.1038/nrc3915

[49]

Sotgia, F. et al. Caveolin-1 and cancer metabolism in the tumor microenvironmen: markers, models, and mechanisms. Annu. Rev. Pathol. 7, 423–467 (2012). 10.1146/annurev-pathol-011811-120856

[50]

Cancer Exosomes Trigger Fibroblast to Myofibroblast Differentiation

Jason Webber, Robert Steadman, Malcolm D. Mason et al.

Cancer Research 2010 10.1158/0008-5472.can-10-1722

Showing 50 of 145 references

Cited By

421

Oxidative stress and cellular senescence: Roles in tumor progression and therapeutic opportunities

Ping Jin, Xu‐Dong Feng · 2024

MedComm – Oncology

Exosome biogenesis: machinery, regulation, and therapeutic implications in cancer

Qing-Fang Han, Wen-Jia Li · 2022

Molecular Cancer

Exosomes as Theranostic Targets: Implications for the Clinical Prognosis of Aggressive Cancers

Richa Gulati, Dhruva Nandi · 2022

Frontiers in Molecular Biosciences

Metrics

421

Citations

145

References

Details

Published: Oct 19, 2020
Vol/Issue: 5(1)
License: View

Authors

University of North Texas

Funding

National Natural Science Foundation of China

Cite This Article

Enli Yang, Xuan Wang, Zhiyuan Gong, et al. (2020). Exosome-mediated metabolic reprogramming: the emerging role in tumor microenvironment remodeling and its influence on cancer progression. Signal Transduction and Targeted Therapy, 5(1). https://doi.org/10.1038/s41392-020-00359-5

Exosome-mediated metabolic reprogramming: the emerging role in tumor microenvironment remodeling and its influence on cancer progression

You May Also Like